Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers

被引:2
|
作者
Gorska, Anna Maria [1 ,2 ]
Santos-Garcia, Irene [1 ,2 ]
Eiriz, Ivan [1 ,2 ]
Bruning, Thomas [1 ,2 ]
Nyman, Tuula [3 ,4 ]
Pahnke, Jens [1 ,2 ,5 ,6 ,7 ,8 ,9 ]
机构
[1] Univ Oslo UiO, Med Fac, Dept Clin Med KlinMed, Translat Neurodegenerat Res & Neuropathol Lab, Sognsvannsveien 20, NO-0372 Oslo, Norway
[2] Oslo Univ Hosp OUS, Dept Pathol, Clin Lab Med KLM, Sect Neuropathol Res, Sognsvannsveien 20, NO-0372 Oslo, Norway
[3] Oslo Univ Hosp OUS, Dept Immunol, Prote Core Facil, Sognsvannsveien 20, NO-0372 Oslo, Norway
[4] Univ Oslo UiO, Fac Med, Prote Core Facil, Sognsvannsveien 20, NO-0372 Oslo, Norway
[5] Univ Lubeck UzL, Inst Nutr Med INUM, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[6] Univ Lubeck UzL, Lubeck Inst Dermatol LIED, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[7] Univ Med Ctr Schleswig Holstein UKSH, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[8] Univ Latvia, Fac Med & Life Sci, Dept Pharmacol, Jelgavas Iela 3, LV-1004 Riga, Latvia
[9] Tel Aviv Univ, Georg S Wise Fac Life Sci, Sch Neurobiol Biochem & Biophys, IL-6997801 Ramat Aviv, Israel
关键词
Alzheimer's disease; CSF; ISF; Proteomics; Biomarkers; Microdialysis; Mass spectrometry; Protein identification; Neurodegeneration; Brain fluids; Expression profiles; AMYLOID PRECURSOR PROTEIN; GSTM1 NULL GENOTYPE; IN-VIVO; BRAIN; MICRODIALYSIS; PLASMA; MODEL; IDENTIFICATION; DEHYDROGENASE; POLYMORPHISM;
D O I
10.1016/j.jneumeth.2024.110239
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Mass spectrometry (MS)-based cerebrospinal fluid (CSF) proteomics is an important method for discovering biomarkers of neurodegenerative diseases. CSF serves as a reservoir for interstitial fluid (ISF), and extensive communication between the two fluid compartments helps to remove waste products from the brain. New method: We performed proteomic analyses of both CSF and ISF fluid compartments using intracerebral microdialysis to validate and detect novel biomarkers of Alzheimer's disease (AD) in APPtg and C57Bl/6J control mice. Results: We identified up to 625 proteins in ISF and 4483 proteins in CSF samples. By comparing the biofluid profiles of APPtg and C57Bl/6J mice, we detected 37 and 108 significantly up- and downregulated candidates, respectively. In ISF, 7 highly regulated proteins, such as Gfap, Aldh1l1, Gstm1, and Txn, have already been implicated in AD progression, whereas in CSF, 9 out of 14 highly regulated proteins, such as Apba2, Syt12, Pgs1 and Vsnl1, have also been validated to be involved in AD pathogenesis. In addition, we also detected new interesting regulated proteins related to the control of synapses and neurotransmission (Kcna2, Cacng3, and Clcn6) whose roles as AD biomarkers should be further investigated. Comparison with existing methods: This newly established combined protocol provides better insight into the mutual communication between ISF and CSF as an analysis of tissue or CSF compartments alone. Conclusions: The use of multiple fluid compartments, ISF and CSF, for the detection of their biological communication enables better detection of new promising AD biomarkers.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    Kaj Blennow
    Harald Hampel
    Michael Weiner
    Henrik Zetterberg
    Nature Reviews Neurology, 2010, 6 : 131 - 144
  • [42] Type 2 diabetes mellitus, brain atrophy and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease
    Moran, Chris
    Beare, Richard
    Thanh Phan
    Bruce, David
    Callisaya, Michele
    Srikanth, Velandai
    AUSTRALASIAN JOURNAL ON AGEING, 2015, 34 : 40 - 40
  • [43] From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S271 - S279
  • [44] Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers
    Algeciras-Schimnich, Alicia
    Bornhorst, Joshua A.
    ALZHEIMERS & DEMENTIA, 2024, 20 (05) : 3657 - 3658
  • [45] Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
    Schindler, Suzanne E.
    Li, Yan
    Todd, Kaitlin W.
    Herries, Elizabeth M.
    Henson, Rachel L.
    Gray, Julia D.
    Wang, Guoqiao
    Graham, Danielle L.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Hassenstab, Jason J.
    Benzinger, Tammie L. S.
    Cruchaga, Carlos
    Jucker, Mathias
    Levin, Johannes
    Chhatwal, Jasmeer P.
    Noble, James M.
    Ringman, John M.
    Graff-Radford, Neill R.
    Holtzman, David M.
    Ladenson, Jack H.
    Morris, John C.
    Bateman, Randall J.
    Xiong, Chengjie
    Fagan, Anne M.
    ALZHEIMERS & DEMENTIA, 2019, 15 (05) : 655 - 665
  • [46] Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis
    Bjerke, Maria
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1199 - 1209
  • [47] Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update
    Portelius, Erik
    Brinkmalm, Gunnar
    Pannee, Josef
    Zetterberg, Henrik
    Blennow, Kaj
    Dahlen, Rahil
    Brinkmalm, Ann
    Gobom, Johan
    EXPERT REVIEW OF PROTEOMICS, 2017, 14 (11) : 1007 - 1020
  • [48] Standardized multiparameter quantification of biomarkers for Alzheimer's disease in cerebrospinal fluid
    Vanderstichele, H
    Demeyer, L
    De Roo, K
    Van Remoortere, S
    Mortier, V
    Olsson, A
    Vandecasteele, L
    Kostanjevecki, V
    Blennow, K
    Vanmechelen, E
    New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2005, 2005, : 183 - 189
  • [49] Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
    Leuzy, Antoine
    Cullen, Nicholas C.
    Mattsson-Carlgren, Niklas
    Hansson, Oskar
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (02) : 266 - 274
  • [50] Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease
    Christoffer Rosén
    Ulf Andreasson
    Niklas Mattsson
    Jan Marcusson
    Lennart Minthon
    Niels Andreasen
    Kaj Blennow
    Henrik Zetterberg
    NeuroMolecular Medicine, 2012, 14 : 65 - 73